1. Home
  2. ACHV vs NYXH Comparison

ACHV vs NYXH Comparison

Compare ACHV & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$2.89

Market Cap

233.2M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$3.09

Market Cap

190.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHV
NYXH
Founded
N/A
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.2M
190.6M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ACHV
NYXH
Price
$2.89
$3.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$15.50
$11.25
AVG Volume (30 Days)
615.8K
64.0K
Earning Date
03-24-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$204.26
Revenue Next Year
$578.60
$136.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$3.02
52 Week High
$6.03
$8.64

Technical Indicators

Market Signals
Indicator
ACHV
NYXH
Relative Strength Index (RSI) 24.33 30.97
Support Level $2.38 N/A
Resistance Level $3.39 $4.99
Average True Range (ATR) 0.25 0.16
MACD -0.15 0.01
Stochastic Oscillator 11.27 11.67

Price Performance

Historical Comparison
ACHV
NYXH

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: